Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
The DOI matches its Crossref record; 164 of the 165 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Our objective was to update the guidelines for the evaluation and treatment of androgen deficiency syndromes in adult men published previously in 2006. PARTICIPANTS: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONCLUSIONS: We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels. We suggest the measurement of morning total testosterone level by a reliable assay as the initial diagnostic test. We recommend confirmation of the diagnosis by repeating the measurement of morning total testosterone and, in some men in whom total testosterone is near the lower limit of normal or in whom SHBG abnormality is suspected by measurement of free or bioavailable testosterone level, using validated assays. We recommend testosterone therapy for men with symptomatic androgen deficiency to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density. We recommend against starting testosterone therapy in patients with breast or prostate cancer, a palpable prostate nodule or induration or prostate-specific antigen greater than 4 ng/ml or greater than 3 ng/ml in men at high risk for prostate cancer such as African-Americans or men with first-degree relatives with prostate cancer without further urological evaluation, hematocrit greater than 50%, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms with International Prostate Symptom Score above 19, or uncontrolled or poorly controlled heart failure. When testosterone therapy is instituted, we suggest aiming at achieving testosterone levels during treatment in the mid-normal range with any of the approved formulations, chosen on the basis of the patient's preference, consideration of pharmacokinetics, treatment burden, and cost. Men receiving testosterone therapy should be monitored using a standardized plan.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To date, the American Association of Clinical Endocrinologists187, the Endocrine Society425 and the Obesity Society186 have not recommended testosterone supplementation as a treatment for sarcopenia or obesity.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [425]
In the citing paper
“In line with this data, the Endocrine Society Guidelines (62) and the Third International Consultation on Sexual Medicine (63) emphasized that lifestyle modifications should be strongly encouraged in hypogonadal subjects with obesity, T2DM, and the MetS.”
From Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis (2013) · cites this paper as [62]
In the citing paper
“T levels demonstrate an age-related decline (96,97).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [97]
In the citing paper
“Current Endocrine Society guidelines recommend measuring fT in men with low-normal TT levels in whom SHBG alterations are suspected with low values established within each laboratory.”
From Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials (2016) · cites this paper as [1]
In the citing paper
“Similarly, guidelines by the Endocrine Society have agreed upon a lower TT threshold for therapeutic consideration at 280–300 ng/dl (9.7–10.4 nmol/L).”
From Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials (2016) · cites this paper as [1]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force elected to use the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) work group, an international group with expertise in development and implementation of evidencebased guidelines (1).”
MethodA Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824 · cited 1×
“Free testosterone level can be measured accurately by equilibrium dialysis or calculated from total testosterone, SHBG, and albumin (20).”
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760 · cited 3×
“The average decline in serum testosterone levels with aging in men is 1–2% per year (7, 8).”
BackgroundThompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Feldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861 · cited 1×
“The average decline in serum testosterone levels with aging in men is 1–2% per year (7, 8).”
BackgroundSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846 · cited 1×
“1 Non-placebo-controlled studies Lowering of testosterone concentrations in adult men by surgical orchiectomy or by GnRH agonist or antagonist administration is associated with rapid and marked loss of bone mineral density (29), increase in fat mass (45), and a TABLE 3.”
BackgroundThe epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294 · cited 1×
“5 mg/d of prednisone or its equivalent increases the risk of gonadotropin and testosterone suppression and alterations in muscle and bone mass (149).”
BackgroundRosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 3×
“Most of the circulating testosterone is bound to SHBG and to albumin (18, 19); only 0.”
BackgroundMethodThe Effect of Finasteride in Men with Benign Prostatic Hyperplasia
Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., Tenover, J. S., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210223271701 · Cited by 1,124
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967
Self-citation
Cited by
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
“The evidence for effects of testosterone replacement on outcomes is mixed, and recent guidelines suggest that screening and treatment of men without symptoms are not recommended (398).”
BackgroundStandards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00229 · Cited by 1,736
Self-citation
Metadata
- Authors
- Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M.
- Affiliations
- Boston University (US)
- Baylor College of Medicine (US)
- University College Dublin (IE)
- University of Washington (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-06
- Volume
- 95
- Issue
- 6
- Pages
- 2536-2559
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2142563833
- Semantic Scholar
- df10a9d7e1ce096bd0507b8f7cbafe35494eee8c
- Cited by
- 1,954
- References
- 165
- Citations by year
- 2026: 23 · 2025: 50 · 2024: 68 · 2023: 66 · 2022: 75 · 2021: 71 · 2020: 85 · 2019: 105 · 2018: 159 · 2017: 211 · 2016: 190 · 2015: 186 · 2014: 228 · 2013: 162 · 2012: 139
- FWCI
- 103.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, hypogonadism, serum total testosterone, sex hormone-binding globulin, prostate-specific antigen, obstructive sleep apnea, heart failure, sexual function, bone mineral density, testosterone formulations, treatment monitoring
- MeSH terms
- Adult, Aged, Androgens, Humans, Hypogonadism, Male, Middle Aged, Monitoring, Physiologic, Sexual Dysfunction, Physiological, Syndrome, Testosterone, HIV Infections, Randomized Controlled Trials as Topic, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. https://app.cochat.ai/papers/10.1210/jc.2009-2354
- The paper
- Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010). Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2009-2354
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.